But the Affordable Care Act of 2010 gave the
The extent to which pharmacists dispense interchangeable biosimilars -- the way they now substitute brand-name, small-molecule drugs with less expensive generics -- will shape a market that holds the potential for great profit.
That potential has led to great interest in how biosimilar medications will reach patients.
"We've got big pharma against new pharma, and we've got chain stores and drugstores and pharmacists, everyone involved in this process,"
Chain drugstores, health insurers and generic drug makers registered their opposition to the House bill, sponsored by state Rep.
State law on generics, which does not address biosimilars, requires pharmacists to notify a purchaser, but not to ask for their written consent. Physicians can note that a brand-name drug must be dispensed as prescribed.
"Legislation like this is a typical brand ploy to thwart competition," said
Generics made up 84 percent of prescriptions dispensed in
Most Popular Stories
- American Airlines, US Airways Complete Merger
- ACA Delay Stresses Small Businesses
- Unemployed Wait as Lawmakers Debate
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Dell Offers Undisclosed Number of Employee Buyouts
- General Dynamics Plans 200 New Jobs in N.M.
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Questions Remain in Jenni Rivera's Death
- U.S. Stocks Rise on Sysco Acquisition
- Harley Issues Motorcycle Recall